Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis

Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis

Abstract Background Intravenous (IV) golimumab, a TNFi, is approved for treating rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). We analyzed pooled safety results from three phase 3 IV golimumab trials in these rheumatologic diseases and hypothesized that the s...

Full description

Bibliographic Details
Main Authors: M. Elaine Husni, Atul Deodhar, Sergio Schwartzman, Soumya D. Chakravarty, Elizabeth C. Hsia, Jocelyn H. Leu, Yiying Zhou, Kim H. Lo, Arthur Kavanaugh
Format: Article
Language:English
Published: BMC 2022-03-01
Series:Arthritis Research & Therapy
Subjects:
Intravenous golimumab
TNF inhibitor
Rheumatoid arthritis
Psoriatic arthritis
Ankylosing spondylitis
Safety
Online Access:https://doi.org/10.1186/s13075-022-02753-6

Internet

https://doi.org/10.1186/s13075-022-02753-6

Similar Items